Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHB-137 in Treatment-naive Participants With CHB
NCT06829329Phase 2Active, not recruiting
- Sponsor
- AusperBio
- Start
- Dec 2024
- Primary completion
- Aug 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of AHB-137 in Chronic Hepatitis B (CHB), sponsored by AusperBio. Started Dec 2024; status: active, not recruiting.
02
Drugs
AHB-137
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06829329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06829329.